Daptomycin is a new lipopeptide antibiotic for which preliminary pharmacokinetic data in adults have been limited to normal healthy volunteers and patients with renal insufficiency. We report the clinical pharmacokinetics of the first and fifth doses of iv daptomycin 150 mg (2 mg/kg) q24h in a 29-year-old man being treated for a gram-positive cellulitis and thrombophlebitis. Individual pharmacokinetic parameters yielded similar results during doses one and five. The pharmacokinetic profile observed in our patient did not markedly differ from data obtained from healthy volunteers.
Get full access to this article
View all access options for this article.
References
1.
RotschaferJCGarrisonMWRodvoldKATherapeutic update on glycopeptide and lipopeptide antibiotics. Pharmacotherapy1988; 8: 211–9.
2.
SextonD.BrownR.McCloskeyR.DowellAR, The Daptomycin Study Group. The use of daptomycin, a lipopeptide antibiotic, in the treatment of gram-positive infections in man (abstract). Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988: 932.
3.
AronoffGRSloanRSLuftFCLY146032 kinetics in normal subjects and patients with renal insufficiency (abstract). Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988: 125.
RodvoldKABlumRAFischerJHVancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother1988; 32: 848–52.
6.
SmithILSchentagJJNoncompartmental determination of steady-state volume of distribution during multiple dosing. J Pharm Sci1984; 73: 281–2.
7.
BrierGLWolnyJDBlackHRProtein binding of daptomycin (abstract) Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 1347.
8.
ChambersHFMillsJ.DrakeTASandeMAFailure of a once daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev Infect Dis1984; 6 (suppl 4): S870–4.
9.
CalainP.KrauseKHVaudauxP.Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis1987; 155: 187–91.
10.
DrusanoGL.Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother1988; 32: 289–97.
